Nurix Therapeutics Inc.

11.89
-0.26 (-2.14%)
At close: Mar 31, 2025, 3:59 PM
12.12
1.86%
After-hours: Mar 31, 2025, 07:59 PM EDT
-2.14%
Bid 11.08
Market Cap 902.67M
Revenue (ttm) 52.79M
Net Income (ttm) -187.34M
EPS (ttm) -2.88
PE Ratio (ttm) -4.13
Forward PE -6.54
Analyst Buy
Ask 12.8
Volume 1,089,391
Avg. Volume (20D) 776,562
Open 11.87
Previous Close 12.15
Day's Range 11.42 - 12.03
52-Week Range 11.38 - 29.56
Beta 2.18

About NRIX

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 286
Stock Exchange NASDAQ
Ticker Symbol NRIX
Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 194.24% from the latest price.

Stock Forecasts

Next Earnings Release

Nurix Therapeutics Inc. is scheduled to release its earnings on Apr 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+6.78%
Nurix Therapeutics shares are trading higher after... Unlock content with Pro Subscription
3 months ago
+6.53%
Nurix Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $35.